WO2004098671A2 - Processes for producing polymer coatings - Google Patents

Processes for producing polymer coatings Download PDF

Info

Publication number
WO2004098671A2
WO2004098671A2 PCT/US2004/014283 US2004014283W WO2004098671A2 WO 2004098671 A2 WO2004098671 A2 WO 2004098671A2 US 2004014283 W US2004014283 W US 2004014283W WO 2004098671 A2 WO2004098671 A2 WO 2004098671A2
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
agent
crosslinking agent
medical device
therapeutic
Prior art date
Application number
PCT/US2004/014283
Other languages
French (fr)
Other versions
WO2004098671A3 (en
Inventor
Samuel J. Epstein
Wendy Naimark
Original Assignee
Scimed Life Systems, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems, Inc filed Critical Scimed Life Systems, Inc
Priority to EP04760732A priority Critical patent/EP1626751A2/en
Publication of WO2004098671A2 publication Critical patent/WO2004098671A2/en
Publication of WO2004098671A3 publication Critical patent/WO2004098671A3/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05DPROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D3/00Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64Animal cells

Definitions

  • the present invention relates to medical devices with polymeric coatings and more particularly to medical devices having polymer coatings that release therapeutic agent.
  • a therapeutic agent is provided within a polymeric carrier layer that is associated with a medical device. Once the medical device is placed at the desired location within a patient, the therapeutic agent is released from the medical device. The desired release profile for the therapeutic agent is dependent upon the particular treatment at hand, including the specific condition being treated/prevented, the specific therapeutic agent selected, the specific site of administration, and so forth.
  • Therapeutic agents are frequently handled in aqueous solutions. Unfortunately, directly coating the surface of a metallic medical device, for example, a stent, with an aqueous solution can be problematic, because metals are typically quite hydrophobic. As a result, the cohesive forces within the aqueous solution tend to pool the solution on the medical device surface, rather than wetting the entire surface. Low coating retention, frequently involving very expensive therapeutic agents, is associated with this phenomenon.
  • a reactive layer comprising a cross-linking agent is initially provided on a medical device surface. Subsequently, a polymer-containing layer comprising a polymer and a therapeutic agent is applied over the reactive layer. Once the two layers have been established, the cross- linking agent from said reactive layer is free to interact with the polymer in the polymer- containing layer, forming a cross-linked polymeric region that contains the therapeutic agent.
  • Examples of medical devices include implantable or insertable medical devices, for example, catheters, balloons, cerebral aneurysm filler coils, arterio-venous shunts and stents.
  • One advantage of the present invention is that a process is provided, which allows for the controlled manufacture of a therapeutic-containing polymer layer on a medical device surface.
  • Another advantage of the present invention is that a process is provided, which allows a hydrophobic medical device surface, such as a metallic surface, to be effectively wetted by an aqueous, or otherwise hydrophilic solution, containing a therapeutic agent, minimizing pooling or beading of the solution.
  • Still another advantage of the present invention is that a coating is provided, which protects the therapeutic agent from rapid release during medical device deployment and also controls release of the therapeutic agent to the target location after deployment.
  • FIG. 1 is a schematic perspective view illustrating a stereo-lithographic deposition technique, in accordance with an embodiment of the present invention.
  • a variety of methods are described below for providing therapeutic-agent-releasing polymer coatings on medical device surfaces. These methods generally comprise the following steps: (a) providing a medical device having on its surface a reactive layer comprising a cross-linking agent; and (b) applying a polymer-containing layer, which comprises a polymer and a therapeutic agent, over the reactive layer. Once the polymer-containing layer is applied, the cross-linking agent from the reactive layer interacts with the polymer species from the polymer- containing layer to form a cross-linked polymeric region.
  • the cross-linked polymeric region contains the therapeutic agent, and can be referred to as a matrix layer or a carrier layer.
  • the cross-linked polymeric region typically (a) acts to retain therapeutic agent during device deployment and (b) releases therapeutic agent in a controlled manner subsequent to device deployment.
  • the use of in situ polymerization reduces the need to handle highly viscous polymer solutions that contain therapeutic agents.
  • Preferred medical devices for use in conjunction with the present invention are implantable or insertable medical devices, including catheters (for example, urinary catheters or vascular catheters such as balloon catheters), guide wires, balloons, filters (e.g., vena cava filters), stents (including coronary vascular stents, cerebral stents, urethral stents, ureteral stents, biliary stents, tracheal stents, gastrointestinal stents and esophageal stents), stent grafts, cerebral aneurysm filler coils (including GDC ⁇ Guglilmi detachable coils—and metal coils), vascular grafts, myocardial plugs, patches, pacemakers and pacemaker leads, heart valves, and biopsy devices; indeed, any substrate (which can be, for example, metallic, polymeric or ceramic, preferably metallic) which is coated in accordance with the present invention and which is designed for use in accordance with the
  • the medical devices for use in connection with the present invention include drug delivery medical devices for systemic treatment or for treatment of any mammalian tissue or organ.
  • treatment refers the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination a disease or condition.
  • Preferred subjects are mammalian subjects and more preferably human subjects.
  • Non-limiting examples of tissues and organs for treatment include the heart, coronary or peripheral vascular system, lungs, trachea, esophagus, brain, liver, kidney, bladder, urethra and ureters, eye, intestines, stomach, colon, pancreas, ovary, prostate, gastrointestinal tract, biliary tract, urinary tract, skeletal muscle, smooth muscle, breast, cartilage and bone.
  • a process comprises: (a) providing a medical device having on its surface a reactive layer that comprises a cross-linking agent; and (b) applying, over the reactive layer, a polymer-containing layer comprising (i) a polymer that is crosslinked by the crosslinking agent and (ii) a therapeutic agent.
  • a polymer-containing layer comprising (i) a polymer that is crosslinked by the crosslinking agent and (ii) a therapeutic agent.
  • the crosslinking agent and the polymer associate with one another, for example, as a result of diffusion and/or any other mass-transport mechanism, leading to crosslinking of the polymer species.
  • the reactive layer and the polymer-containing layer are preferably sufficiently reactive with one another to lead to crosslinking of essentially all of the polymer within the polymer- containing layer by the crosslinking agent.
  • a "polymer” is any macromolecule composed of two or more monomers, and includes dimers, trimers, tetramers, etc.
  • a "monomer” is a polymerizable molecule.
  • the polymers of the present invention will have a median number of monomers that numbers in the tens (10 to 99), hundreds (100 to 999), thousands (1000 to 9999), tens of thousands (10,000 to 99,999) or more.
  • a "cross-linking agent” is any species that is capable of linking a first polymer chain to a second polymer chain.
  • Linking can be covalent or non-covalent (e.g., ionic). In some instances, at least a portion of the crosslinking agent becomes incorporated into the crosslinked composition.
  • Crosslinkable polymers for use in connection with the present invention may be crosslinked using either non-ionic crosslinking (e.g., covalent crosslinking) or ionic crosslinking.
  • Crosslinkable polymers suitable for the practice of the present invention include carboxylic, sulfate, hydroxy and amine-functionalized polymers, among others.
  • Suitable crosslinkable polymers which may be used in the practice of the present invention include homopolymers, copolymers and polymer blends comprising one or more of the following: polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly (N-vinyl pyrrolidone), polyethylene oxide, hydrolyzed polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polyethylene amine, alginic acid, pectinic acid, carboxy methyl cellulose, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar
  • Ionic crosslinking agents may be in the form of anions or cations, depending on whether the polymer to be crosslinked is cationically or anionically crosslinkable.
  • Appropriate cationic crosslinking agents include alkaline earth metals, such as calcium, magnesium, barium, strontium, and beryllium ions; transition metals, such as iron, manganese, copper, cobalt, zinc, and silver ions; other metallic elements, such as boron, aluminum, lead, and bismuth ions; and polyamonium ions, such as + H 3 N(-H 2 ) n - NH 3 + or + H 3 N-(CH 2 ) n -CH((CH 2 ) m -NH 3 + )((CH 2 ) P -NH 3 + ) where n is an integer ranging from 1 to 8, and m and p are integers ranging from 0 to 8.
  • Preferred cationic crosslinking agents are calcium and barium ions.
  • Anionic crosslinking agents appropriate for the practice of the present invention include those derived from polybasic organic or inorganic acids.
  • Appropriate anionic crosslinking agents include phosphate, sulfate, citrate, borate, succinate, maleate, adipate, and oxalate ions.
  • One preferred embodiment of the present invention utilizes the following: (a) a reactive layer comprising a multivalent cationic crosslinking agent (e.g., calcium or barium) and (b) a polymer-containing layer comprising (i) one or more mono-valent salts of alginic acid (e.g., sodium alginate and/or potassium alginate) and (ii) a therapeutic agent.
  • a reactive layer comprising a multivalent cationic crosslinking agent (e.g., calcium or barium)
  • a polymer-containing layer comprising (i) one or more mono-valent salts of alginic acid (e.g., sodium alginate and/or potassium alginate) and (ii) a therapeutic agent.
  • alginic acid e.g., sodium alginate and/or potassium alginate
  • a therapeutic agent e.g., sodium alginate and/or potassium alginate
  • Ionically crosslinked systems are particularly advantageous when used in connection with medical devices having hydrophobic surfaces.
  • the salts that are typically used to provide the cationic or anionic crosslinking agent also act to reduce the surface tension of the solution (generally aqueous) that is applied to the hydrophobic surface. As a result, coating retention is increased.
  • such salts are typically inexpensive as compared to the therapeutic agent that is found in the polymer- containing layer.
  • retention of the subsequently applied polymer-containing layer, and hence retention of therapeutic agent is improved.
  • crosslinking agents are frequently of low molecular weight, and hence of high mobility, enhancing interactions between the crosslinking agent and the polymer.
  • Preferred non-ionic crosslinking agents are those that react with groups present in the polymer such that covalent bonds are formed between different polymer chains.
  • Suitable non-ionic crosslinking agents are polyfunctional compounds having at least two functional groups reactive with one or more functional groups present in the polymer(s).
  • Exemplary crosslinking agents contain one or more of the following: carboxy groups, hydroxy groups, epoxy groups, halogen groups amino functional groups, or hydrogen unsaturated groups, which are capable of undergoing facile nucleophilic or condensation reactions with groups present in the polymer at temperatures up to about 100°C.
  • Suitable crosslinking reagents include polycarboxylic acids or anhydrides; polyamines; epihalohydrins; diepoxides; dialdehydes (e.g., glutaraldehyde); diols; carboxylic acid halides, ketones and like compounds.
  • the polymer-containing layer can comprise either (a) a polymer containing both lysine and glutamine or (b) a polymer containing lysine and a polymer containing glutamine.
  • a corresponding crosslinking agent appropriate for use in this reactive layer is a transglutaminase enzyme.
  • the transglutaminase enzyme from the reactive layer acts to covalently bond the glutamine and lysine within the polymer(s) in the presence of the therapeutic agent, forming a cross-linked therapeutic-agent-containing matrix.
  • the reactive layer can be applied on the medical device surface by any appropriate method. Preferred techniques include casting, spin coating, web coating, stereo-lithographic deposition, spraying, dipping, coating via air suspension and mechanical suspension techniques, positive displacement coating techniques, ink jet techniques, electrostatic techniques, and combinations of these processes. Spraying is a frequently used technique where coating retention is not of great concern (e.g., where the cost of the materials present in the crosslinking agent are relatively low).
  • the polymer-containing layer is subsequently deposited over the reactive layer.
  • the cross-linkable polymer and the therapeutic agent are dissolved or dispersed in a carrier liquid, for example, water or an organic liquid. Because therapeutic agents are commonly handled in aqueous solutions, water is commonly preferred.
  • a carrier liquid for example, water or an organic liquid. Because therapeutic agents are commonly handled in aqueous solutions, water is commonly preferred.
  • the polymer-containing layer can be applied over the reactive layer by any appropriate method, include the techniques set forth above. As previously noted, therapeutic agents are, in general, quite expensive. Hence, it is typically desirable to use techniques having high coating retention, of which stereo-lithographic deposition is one example.
  • Stereo-lithographic deposition is a process by which material can be applied onto a surface to obtain a 3-dimentional structure. This structure can be created through repetitive layering of the coating material.
  • SLD can provide the means for building a therapeutic coating in a specific location.
  • a stent element 12 is illustrated, to which a reactive layer (not separately illustrated) has previously been applied.
  • a nozzle 14 dispenses the polymer-containing layer 16 over the stent element 12, precisely directing the deposition location of the polymer-containing layer 16.
  • the polymer within the polymer-containing layer 16 reacts with the crosslinking agent that is present on the surface to form therapeutic-agent-containing crosslinked polymer network.
  • the crosslinked network is securely attached to the stent surface.
  • the resulting crosslinked network is preferably sufficiently durable to withstand stent crimping and expansion.
  • One illustrative analog of SLD would be writing on a radiator grill with a tube of toothpaste.
  • the nozzle of the toothpaste tube allows one to control the lay of the bead of toothpaste. Pressure on the tube and the distance of the nozzle from the grill surface can control the thickness of the bead.
  • the viscosity of the SLD coating material is high enough to facilitate such a toothpaste analogy. However, this is not always the case. Nonetheless, in the event that a low viscosity polymer-containing layer is deposited using the SLD process, the process of the present invention will render the polymer-containing layer more viscous upon contacting the surface due to the crosslinking that subsequently occurs, improving coating retention.
  • the reactive layer generally presents a relatively hydrophilic surface for the subsequently applied polymer-containing layer.
  • an aqueous-based liquid is applied to create the polymer-containing layer, the presence of this hydrophilic surface further improves coating retention and uniformity.
  • other techniques other than SLD can be used to create the polymer-containing layer.
  • coating thickness can be varied, for example, by modification of coating process parameters, including increasing spray flow rate, slowing movement between the substrate to be coated and the spray nozzle, providing repeated passes, and so forth.
  • non-genetic therapeutic agents include genetic therapeutic agents, non-genetic therapeutic agents and cells.
  • exemplary non-genetic therapeutic agents for the practice of the invention include: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopept
  • Exemplary genetic therapeutic agents for the practice of the invention include anti-sense DNA and RNA as well as DNA coding for: (a) anti-sense RNA, (b) tRNA or rRNA to replace defective or deficient endogenous molecules, (c) angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor ⁇ and ⁇ , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor ⁇ , hepatocyte growth factor and insulin-like growth factor, (d) cell cycle inhibitors including CD inhibitors, and (e) thymidine kinase ("TK”) and other agents useful for interfering with cell proliferation.
  • TK thymidine kinase
  • BMP's bone morphogenic proteins
  • BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7 are preferred.
  • dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules.
  • molecules capable of inducing an upstream or downstream effect of a BMP can be provided.
  • Such molecules include any of the "hedgehog" proteins, or the DNA's encoding them.
  • Some additional exemplary genetic therapeutic agents for the practice of the invention include DNA encoding for the following: cytokines such as colony stimulating factors (e.g., granulocyte-macrophage colony-stimulating factor), tumor necrosis factors (e.g., fas ligand) and interleukins (e.g., IL-10, an anti-inflammatory interleukin), as well as protease inhibitors, particularly serine protease inhibitors (e.g., SERP-1), tissue inhibiting metalloproteinases (e.g., TIMP-1, TIMP-2, TIMP-3, TIMP-4), monocyte chemoattractant proteins (e.g., MCP-1), protein kinase inhibitors including cyclin- dependent kinase inhibitors (e.g., p27, p21), endogenous and inducible nitric oxide synthase, CO-generating enzymes, such as hemoxygenases, which catalyze the cytok
  • Vectors for delivery of genetic therapeutic agents include viral vectors such as adenoviruses, gutted adenoviruses, adeno-associated virus, retroviruses, alpha virus (Semliki Forest, Sindbis, etc.), lentiviruses, herpes simplex virus, replication competent viruses (e.g., ONYX-015) and hybrid vectors; and non- viral vectors such as artificial chromosomes and mini-chromosomes, plasmid DNA vectors (e.g., pCOR), cationic polymers (e.g., polyethyleneimine, polyethyleneimine (PEI)), graft copolymers (e.g., polyether-PEI and polyethylene oxide-PEI), neutral polymers PVP, SP1017 (SUPRATEK), lipids such as cationic lipids, liposomes, lipoplexes, nanoparticles, or microparticles, with and without targeting sequences such as the protein transduction domain (PTD
  • agents include one or more of the following: (a) Ca-channel blockers including benzothiazapines such as diltiazem and clentiazem, dihydropyridines such as nifedipine, amlodipine and nicardapine, and phenylalkylamines such as verapamil, (b) serotonin pathway modulators including: 5-HT antagonists such as ketanserin and naftidrofuryl, as well as 5-HT uptake inhibitors such as fluoxetine, (c) cyclic nucleotide pathway agents including phosphodiesterase inhibitors such as cilostazole and dipyridamole, adenylate/guanylate cyclase stimulants such as forskolin, as well as adenos
  • Therapeutic agents may be used singly or in combination.
  • a wide range of therapeutic agent loadings can be used in connection with the above polymeric coatings, with the amount of loading being readily determined by those of ordinary skill in the art and ultimately depending upon the condition to be treated, the nature of the therapeutic agent itself, the avenue by which the therapeutic-agent-loaded polymeric coating is administered to the intended subject, and so forth.
  • the loaded polymeric coating will frequently comprise from 1% or less to 70 wt% or more therapeutic agent.
  • a cross-linking agent is applied to the surface of a stent.
  • the therapeutic is then delivered to the stent surface within a polymer solution.
  • the polymer solution contacts the cross-linking agent on the surface of the stent, the polymer forms a gel, and the therapeutic is held in a crosslinked matrix on the surface of the stent.
  • Stents are initially spray coated with the CaCl 2 solution and allowed to dry for 3 hours at 37°C.
  • Sodium Alginate solution is then loaded into hypodermic syringe using care to eliminate any bubbles in the syringe.
  • Dried stents are loaded onto mandrels, and using the light microscope, the needle tip is moved into a position directly over a CaCl 2 - coated stent strut.
  • Gentle pressure is used to introduce the alginate solution from the needle to the stent surface.
  • the stent strut can be thought of as corresponding to numeral 12, the needle to numeral 14, and the alginate solution to numeral 16.
  • the sodium alginate which is a yellowish color, turns a noticeable shade of green. There appears to be some volume loss (shrinking) of the alginate as it gels as well. Alginate gels anywhere that CaCl 2 is present, but it does not do so on bare metal. Scratching the surface with a needle after depositing the alginate reveals a gel-like substance. Prolonged exposure to the microscope lights appears to dry the alginate gel and create a crystalline surface.

Abstract

A method for furnishing a therapeutic-agent-containing medical device is provided. The method comprises: (a) providing a reactive layer comprising a crosslinking agent on a medical device surface; and (b) subsequently applying a polymercontaining layer, which comprises a polymer and a therapeutic agent, over the reactive layer. The cross­linking agent interacts with the polymer to form a cross-linked polymeric region that comprises the therapeutic agent. Examples of medical devices include implantable or insertable medical devices, for example, catheters, balloon, cerebral aneurysm filler coils, arterio-venous shunts and stents.

Description

PROCESSES FOR PRODUCING POLYMER COATINGS FOR RELEASE OF THERAPEUTIC AGENT
BACKGROUND OF THE INVENTION
1. Field of the Invention [0001] The present invention relates to medical devices with polymeric coatings and more particularly to medical devices having polymer coatings that release therapeutic agent.
2. Brief Description of the Background Art [0002] Numerous medical devices have been developed for the delivery of therapeutic agents to the body. For example, in accordance with some delivery strategies, a therapeutic agent is provided within a polymeric carrier layer that is associated with a medical device. Once the medical device is placed at the desired location within a patient, the therapeutic agent is released from the medical device. The desired release profile for the therapeutic agent is dependent upon the particular treatment at hand, including the specific condition being treated/prevented, the specific therapeutic agent selected, the specific site of administration, and so forth. [0003] Therapeutic agents are frequently handled in aqueous solutions. Unfortunately, directly coating the surface of a metallic medical device, for example, a stent, with an aqueous solution can be problematic, because metals are typically quite hydrophobic. As a result, the cohesive forces within the aqueous solution tend to pool the solution on the medical device surface, rather than wetting the entire surface. Low coating retention, frequently involving very expensive therapeutic agents, is associated with this phenomenon.
SUMMARY OF THE INVENTION
[0004] The above and other issues are addressed by the present invention, in which a novel method is provided for producing a therapeutic agent releasing medical device. [0005] According one embodiment of the present invention, a reactive layer comprising a cross-linking agent is initially provided on a medical device surface. Subsequently, a polymer-containing layer comprising a polymer and a therapeutic agent is applied over the reactive layer. Once the two layers have been established, the cross- linking agent from said reactive layer is free to interact with the polymer in the polymer- containing layer, forming a cross-linked polymeric region that contains the therapeutic agent.
[0006] Examples of medical devices include implantable or insertable medical devices, for example, catheters, balloons, cerebral aneurysm filler coils, arterio-venous shunts and stents.
[0007] One advantage of the present invention is that a process is provided, which allows for the controlled manufacture of a therapeutic-containing polymer layer on a medical device surface.
[0008] Another advantage of the present invention is that a process is provided, which allows a hydrophobic medical device surface, such as a metallic surface, to be effectively wetted by an aqueous, or otherwise hydrophilic solution, containing a therapeutic agent, minimizing pooling or beading of the solution.
[0009] Still another advantage of the present invention is that a coating is provided, which protects the therapeutic agent from rapid release during medical device deployment and also controls release of the therapeutic agent to the target location after deployment. [0010] The above and other embodiments and advantages of the present invention will be readily understood by those of ordinary skill in the art upon review of the Detailed Description and Claims to follow.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] FIG. 1 is a schematic perspective view illustrating a stereo-lithographic deposition technique, in accordance with an embodiment of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0012] In accordance with the present invention, a variety of methods are described below for providing therapeutic-agent-releasing polymer coatings on medical device surfaces. These methods generally comprise the following steps: (a) providing a medical device having on its surface a reactive layer comprising a cross-linking agent; and (b) applying a polymer-containing layer, which comprises a polymer and a therapeutic agent, over the reactive layer. Once the polymer-containing layer is applied, the cross-linking agent from the reactive layer interacts with the polymer species from the polymer- containing layer to form a cross-linked polymeric region. The cross-linked polymeric region contains the therapeutic agent, and can be referred to as a matrix layer or a carrier layer.
[0013] Once formed, the cross-linked polymeric region typically (a) acts to retain therapeutic agent during device deployment and (b) releases therapeutic agent in a controlled manner subsequent to device deployment. The use of in situ polymerization reduces the need to handle highly viscous polymer solutions that contain therapeutic agents.
[0014] Preferred medical devices for use in conjunction with the present invention are implantable or insertable medical devices, including catheters (for example, urinary catheters or vascular catheters such as balloon catheters), guide wires, balloons, filters (e.g., vena cava filters), stents (including coronary vascular stents, cerebral stents, urethral stents, ureteral stents, biliary stents, tracheal stents, gastrointestinal stents and esophageal stents), stent grafts, cerebral aneurysm filler coils (including GDC~Guglilmi detachable coils—and metal coils), vascular grafts, myocardial plugs, patches, pacemakers and pacemaker leads, heart valves, and biopsy devices; indeed, any substrate (which can be, for example, metallic, polymeric or ceramic, preferably metallic) which is coated in accordance with the present invention and which is designed for use in a patient, either for procedural use or as an implant.
[0015] The medical devices for use in connection with the present invention include drug delivery medical devices for systemic treatment or for treatment of any mammalian tissue or organ. As used herein, "treatment" refers the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination a disease or condition. Preferred subjects are mammalian subjects and more preferably human subjects. Non-limiting examples of tissues and organs for treatment include the heart, coronary or peripheral vascular system, lungs, trachea, esophagus, brain, liver, kidney, bladder, urethra and ureters, eye, intestines, stomach, colon, pancreas, ovary, prostate, gastrointestinal tract, biliary tract, urinary tract, skeletal muscle, smooth muscle, breast, cartilage and bone. [0016] As previously indicated, in accordance with various embodiments of the present invention, a process is provided that comprises: (a) providing a medical device having on its surface a reactive layer that comprises a cross-linking agent; and (b) applying, over the reactive layer, a polymer-containing layer comprising (i) a polymer that is crosslinked by the crosslinking agent and (ii) a therapeutic agent. After the polymer-containing layer is established over the reactive layer, the crosslinking agent and the polymer associate with one another, for example, as a result of diffusion and/or any other mass-transport mechanism, leading to crosslinking of the polymer species. The reactive layer and the polymer-containing layer are preferably sufficiently reactive with one another to lead to crosslinking of essentially all of the polymer within the polymer- containing layer by the crosslinking agent.
[0017] A "polymer" is any macromolecule composed of two or more monomers, and includes dimers, trimers, tetramers, etc. A "monomer" is a polymerizable molecule. Typically, the polymers of the present invention will have a median number of monomers that numbers in the tens (10 to 99), hundreds (100 to 999), thousands (1000 to 9999), tens of thousands (10,000 to 99,999) or more.
[0018] A "cross-linking agent" is any species that is capable of linking a first polymer chain to a second polymer chain. Linking can be covalent or non-covalent (e.g., ionic). In some instances, at least a portion of the crosslinking agent becomes incorporated into the crosslinked composition.
[0019] Crosslinkable polymers for use in connection with the present invention may be crosslinked using either non-ionic crosslinking (e.g., covalent crosslinking) or ionic crosslinking.
[0020] Crosslinkable polymers suitable for the practice of the present invention include carboxylic, sulfate, hydroxy and amine-functionalized polymers, among others. Suitable crosslinkable polymers which may be used in the practice of the present invention include homopolymers, copolymers and polymer blends comprising one or more of the following: polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly (N-vinyl pyrrolidone), polyethylene oxide, hydrolyzed polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polyethylene amine, alginic acid, pectinic acid, carboxy methyl cellulose, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar, potassium polymetaphosphates (e.g., Kurrol salts), cationic starch, as well as acid salts and esters thereof where appropriate. [0021] Ionic crosslinking agents may be in the form of anions or cations, depending on whether the polymer to be crosslinked is cationically or anionically crosslinkable. [0022] Appropriate cationic crosslinking agents include alkaline earth metals, such as calcium, magnesium, barium, strontium, and beryllium ions; transition metals, such as iron, manganese, copper, cobalt, zinc, and silver ions; other metallic elements, such as boron, aluminum, lead, and bismuth ions; and polyamonium ions, such as +H3N(-H2)n- NH3 + or +H3N-(CH2) n-CH((CH2) m-NH3 +)((CH2) P-NH3 +) where n is an integer ranging from 1 to 8, and m and p are integers ranging from 0 to 8. Preferred cationic crosslinking agents are calcium and barium ions.
[0023] Anionic crosslinking agents appropriate for the practice of the present invention include those derived from polybasic organic or inorganic acids. Appropriate anionic crosslinking agents include phosphate, sulfate, citrate, borate, succinate, maleate, adipate, and oxalate ions.
[0024] One preferred embodiment of the present invention utilizes the following: (a) a reactive layer comprising a multivalent cationic crosslinking agent (e.g., calcium or barium) and (b) a polymer-containing layer comprising (i) one or more mono-valent salts of alginic acid (e.g., sodium alginate and/or potassium alginate) and (ii) a therapeutic agent. In this embodiment, upon application of the polymer-containing layer over the reactive layer, the divalent cations from the reactive layer interact with the alginate polymers from the polymer-containing layer, in the presence of the therapeutic agent, resulting in the formation of a cross-linked, therapeutic-agent-containing matrix. [0025] Ionically crosslinked systems are particularly advantageous when used in connection with medical devices having hydrophobic surfaces. This is because the salts that are typically used to provide the cationic or anionic crosslinking agent also act to reduce the surface tension of the solution (generally aqueous) that is applied to the hydrophobic surface. As a result, coating retention is increased. Moreover, such salts are typically inexpensive as compared to the therapeutic agent that is found in the polymer- containing layer. By establishing a relatively hydrophilic, salt-containing layer upon the device surface, retention of the subsequently applied polymer-containing layer, and hence retention of therapeutic agent, is improved. Furthermore, such crosslinking agents are frequently of low molecular weight, and hence of high mobility, enhancing interactions between the crosslinking agent and the polymer. [0026] Preferred non-ionic crosslinking agents are those that react with groups present in the polymer such that covalent bonds are formed between different polymer chains. Suitable non-ionic crosslinking agents are polyfunctional compounds having at least two functional groups reactive with one or more functional groups present in the polymer(s). Exemplary crosslinking agents contain one or more of the following: carboxy groups, hydroxy groups, epoxy groups, halogen groups amino functional groups, or hydrogen unsaturated groups, which are capable of undergoing facile nucleophilic or condensation reactions with groups present in the polymer at temperatures up to about 100°C. Suitable crosslinking reagents include polycarboxylic acids or anhydrides; polyamines; epihalohydrins; diepoxides; dialdehydes (e.g., glutaraldehyde); diols; carboxylic acid halides, ketones and like compounds.
[0027] Other exemplary crosslinkable polymers for the practice of the present invention include polymers that contain amino acids (e.g., proteins), which can be covalently crosslinked to one another using an appropriate crosslinking agent. For example, the polymer-containing layer can comprise either (a) a polymer containing both lysine and glutamine or (b) a polymer containing lysine and a polymer containing glutamine. A corresponding crosslinking agent appropriate for use in this reactive layer is a transglutaminase enzyme. Upon application of the polymer-containing layer to the reactive layer, the transglutaminase enzyme from the reactive layer acts to covalently bond the glutamine and lysine within the polymer(s) in the presence of the therapeutic agent, forming a cross-linked therapeutic-agent-containing matrix. [0028] The reactive layer can be applied on the medical device surface by any appropriate method. Preferred techniques include casting, spin coating, web coating, stereo-lithographic deposition, spraying, dipping, coating via air suspension and mechanical suspension techniques, positive displacement coating techniques, ink jet techniques, electrostatic techniques, and combinations of these processes. Spraying is a frequently used technique where coating retention is not of great concern (e.g., where the cost of the materials present in the crosslinking agent are relatively low). [0029] The polymer-containing layer is subsequently deposited over the reactive layer. Preferably the cross-linkable polymer and the therapeutic agent are dissolved or dispersed in a carrier liquid, for example, water or an organic liquid. Because therapeutic agents are commonly handled in aqueous solutions, water is commonly preferred. [0030] The polymer-containing layer can be applied over the reactive layer by any appropriate method, include the techniques set forth above. As previously noted, therapeutic agents are, in general, quite expensive. Hence, it is typically desirable to use techniques having high coating retention, of which stereo-lithographic deposition is one example.
[0031] Stereo-lithographic deposition (SLD) is a process by which material can be applied onto a surface to obtain a 3-dimentional structure. This structure can be created through repetitive layering of the coating material. In the case of small medical devices, such as endoluminal stents, SLD can provide the means for building a therapeutic coating in a specific location.
[0032] Referring now to Fig. 1, for example, a stent element 12 is illustrated, to which a reactive layer (not separately illustrated) has previously been applied. A nozzle 14 dispenses the polymer-containing layer 16 over the stent element 12, precisely directing the deposition location of the polymer-containing layer 16. After deposition, the polymer within the polymer-containing layer 16 reacts with the crosslinking agent that is present on the surface to form therapeutic-agent-containing crosslinked polymer network. Upon drying, the crosslinked network is securely attached to the stent surface. The resulting crosslinked network is preferably sufficiently durable to withstand stent crimping and expansion.
[0033] One illustrative analog of SLD would be writing on a radiator grill with a tube of toothpaste. The nozzle of the toothpaste tube allows one to control the lay of the bead of toothpaste. Pressure on the tube and the distance of the nozzle from the grill surface can control the thickness of the bead. Sometimes, the viscosity of the SLD coating material is high enough to facilitate such a toothpaste analogy. However, this is not always the case. Nonetheless, in the event that a low viscosity polymer-containing layer is deposited using the SLD process, the process of the present invention will render the polymer-containing layer more viscous upon contacting the surface due to the crosslinking that subsequently occurs, improving coating retention. [0034] Moreover, as indicated above, the reactive layer generally presents a relatively hydrophilic surface for the subsequently applied polymer-containing layer. Where an aqueous-based liquid is applied to create the polymer-containing layer, the presence of this hydrophilic surface further improves coating retention and uniformity. [0035] Of course, other techniques other than SLD can be used to create the polymer-containing layer. One preferred technique, particularly where high coating retention is not required, is spray coating. As with SLD, coating thickness can be varied, for example, by modification of coating process parameters, including increasing spray flow rate, slowing movement between the substrate to be coated and the spray nozzle, providing repeated passes, and so forth.
[0036] "Therapeutic agents", "pharmaceutically active agents", "pharmaceutically active materials", "drugs" and other related terms may be used interchangeably herein and include genetic therapeutic agents, non-genetic therapeutic agents and cells. [0037] Exemplary non-genetic therapeutic agents for the practice of the invention include: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, and thymidine kinase inhibitors; (d) anesthetic agents such as lidocaine, bupivacaine and ropivacaine; (e) anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; (f) vascular cell growth promoters such as growth factors, transcriptional activators, and translational promotors; (g) vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase and tyrosine kinase inhibitors (e.g., tyrphostins, genistein, quinoxalines); (i) prostacyclin analogs; (j) cholesterol-lowering agents; (k) angiopoietins; (1) antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; (m) cytotoxic agents, cytostatic agents and cell proliferation affectors; (n) vasodilating agents; and (o)agents that interfere with endogenous vasoactive mechanisms. [0038] Exemplary genetic therapeutic agents for the practice of the invention include anti-sense DNA and RNA as well as DNA coding for: (a) anti-sense RNA, (b) tRNA or rRNA to replace defective or deficient endogenous molecules, (c) angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin-like growth factor, (d) cell cycle inhibitors including CD inhibitors, and (e) thymidine kinase ("TK") and other agents useful for interfering with cell proliferation. Also of interest is DNA encoding for the family of bone morphogenic proteins ("BMP's"), including BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively, or in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNA's encoding them.
[0039] Some additional exemplary genetic therapeutic agents for the practice of the invention include DNA encoding for the following: cytokines such as colony stimulating factors (e.g., granulocyte-macrophage colony-stimulating factor), tumor necrosis factors (e.g., fas ligand) and interleukins (e.g., IL-10, an anti-inflammatory interleukin), as well as protease inhibitors, particularly serine protease inhibitors (e.g., SERP-1), tissue inhibiting metalloproteinases (e.g., TIMP-1, TIMP-2, TIMP-3, TIMP-4), monocyte chemoattractant proteins (e.g., MCP-1), protein kinase inhibitors including cyclin- dependent kinase inhibitors (e.g., p27, p21), endogenous and inducible nitric oxide synthase, CO-generating enzymes, such as hemoxygenases, which catalyze the oxidation of heme into the biologically active molecules iron biliverdin and CO (e.g., HOI-1), antiproliferative compounds, such as hKIS in a transdominant mutant peptide form, which are capable of interfering with the ability of endogenous hKIS to phosphorylate p27 thereby enhancing cell cycle arrest, as well as derivatives of the foregoing. [0040] Vectors for delivery of genetic therapeutic agents include viral vectors such as adenoviruses, gutted adenoviruses, adeno-associated virus, retroviruses, alpha virus (Semliki Forest, Sindbis, etc.), lentiviruses, herpes simplex virus, replication competent viruses (e.g., ONYX-015) and hybrid vectors; and non- viral vectors such as artificial chromosomes and mini-chromosomes, plasmid DNA vectors (e.g., pCOR), cationic polymers (e.g., polyethyleneimine, polyethyleneimine (PEI)), graft copolymers (e.g., polyether-PEI and polyethylene oxide-PEI), neutral polymers PVP, SP1017 (SUPRATEK), lipids such as cationic lipids, liposomes, lipoplexes, nanoparticles, or microparticles, with and without targeting sequences such as the protein transduction domain (PTD), as well as other transfection enhancing agents. [0041] Cells include cells of human origin (autologous or allogeneic), including stem cells, or from an animal source (xenogeneic), which can be genetically engineered if desired to deliver proteins of interest.
[0042] Numerous therapeutic agents, not necessarily exclusive of those listed above, have been identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis. Such agents are appropriate for the practice of the present invention and include one or more of the following: (a) Ca-channel blockers including benzothiazapines such as diltiazem and clentiazem, dihydropyridines such as nifedipine, amlodipine and nicardapine, and phenylalkylamines such as verapamil, (b) serotonin pathway modulators including: 5-HT antagonists such as ketanserin and naftidrofuryl, as well as 5-HT uptake inhibitors such as fluoxetine, (c) cyclic nucleotide pathway agents including phosphodiesterase inhibitors such as cilostazole and dipyridamole, adenylate/guanylate cyclase stimulants such as forskolin, as well as adenosine analogs, (d) catecholamine modulators including α-antagonists such as prazosin and bunazosine, β-antagonists such as propranolol and α/β-antagonists such as labetalol and carvedilol, (e) endothelin receptor antagonists, (f) nitric oxide donors/releasing molecules including organic nitrates/nitrites such as nitroglycerin, isosorbide dinitrate and amyl nitrite, inorganic nitroso compounds such as sodium nitroprusside, sydnonimines such as molsidomine and linsidomine, nonoates such as diazenium diolates and NO adducts of alkanediamines, S-nitroso compounds including low molecular weight compounds (e.g., S-nitroso derivatives of captopril, glutathione and N-acetyl penicillamine) and high molecular weight compounds (e.g., S-nitroso derivatives of proteins, peptides, oligosaccharides, polysaccharides, synthetic polymers/oligomers and natural polymers/oligomers), as well as C-nitroso-compounds, O-nitroso-compounds, N-nitroso- compounds and L-arginine, (g) ACE inhibitors such as cilazapril, fosinopril and enalapril, (h) ATII-receptor antagonists such as saralasin and losartin, (i) platelet adhesion inhibitors such as albumin and polyethylene oxide, (j) platelet aggregation inhibitors including aspirin and thienopyridine (ticlopidine, clopidogrel) and GP Ilb/IIIa inhibitors such as abciximab, epitifibatide and tirofiban, (k) coagulation pathway modulators including heparinoids such as heparin, low molecular weight heparin, dextran sulfate and β-cyclodextrin tetradecasulfate, thrombin inhibitors such as hirudin, hirulog, PPACK(D- phe-L-propyl-L-arg-chloromethylketone) and argatroban, FXa inhibitors such as antistatin and TAP (tick anticoagulant peptide), Vitamin K inhibitors such as warfarin, as well as activated protein C, (1) cyclooxygenase pathway inhibitors such as aspirin, ibuprofen, flurbiprofen, indomethacin and sulfinpyrazone, (m) natural and synthetic corticosteroids such as dexamethasone, prednisolone, methprednisolone and hydrocortisone, (n) lipoxygenase pathway inhibitors such as nordihydroguairetic acid and caffeic acid, (o) leukotriene receptor antagonists, (p) antagonists of E- and P-selectins, (q) inhibitors of VCAM-1 and ICAM-1 interactions, (r) prostaglandins and analogs thereof including prostaglandins such as PGE1 and PGI2 and prostacyclin analogs such as ciprostene, epoprostenol, carbacyclin, iloprost and beraprost, (s) macrophage activation preventers including bisphosphonates, (t) HMG-CoA reductase inhibitors such as lovastatin, pravastatin, fluvastatin, simvastatin and cerivastatin, (u) fish oils and omega-3- fatty acids, (v) free-radical scavengers/antioxidants such as probucol, vitamins C and E, ebselen, trans-retinoic acid and SOD mimics, (w) agents affecting various growth factors including FGF pathway agents such as bFGF antibodies and chimeric fusion proteins, PDGF receptor antagonists such as trapidil, IGF pathway agents including somatostatin analogs such as angiopeptin and ocreotide, TGF-β pathway agents such as polyanionic agents (heparin, fucoidin), decorin, and TGF-β antibodies, EGF pathway agents such as EGF antibodies, receptor antagonists and chimeric fusion proteins, TNF-α pathway agents such as thalidomide and analogs thereof, Thromboxane A2 (TXA2) pathway modulators such as sulotroban, vapiprost, dazoxiben and ridogrel, as well as protein tyrosine kinase inhibitors such as tyrphostin, genistein and quinoxaline derivatives, (x) MMP pathway inhibitors such as marimastat, ilomastat and metastat, (y) cell motility inhibitors such as cytochalasin B, (z) antiproliferative/antineoplastic agents including antimetabolites such as purine analogs (e.g., 6-mercaptopurine or cladribine, which is a chlorinated purine nucleoside analog), pyrimidine analogs (e.g., cytarabine and 5- fluorouracil) and methotrexate , nitrogen mustards, alkyl sulfonates, ethylenimines, antibiotics (e.g., daunorubicin, doxorubicin), nitrosoureas, cisplatin, agents affecting microtubule dynamics (e.g., vinblastine, vincristine, colchicine, paclitaxel and epothilone), caspase activators, proteasome inhibitors, angiogenesis inhibitors (e.g., endostatin, angiostatin and squalamine), rapamycin, cerivastatin, flavopiridol and suramin, (aa) matrix deposition/organization pathway inhibitors such as halofuginone or other quinazolinone derivatives and tranilast, (bb) endothelialization facilitators such as VEGF and RGD peptide, (cc) blood rheology modulators such as pentoxifylline, and (dd) endothelial-cell specific mitogens.
[0043] Several of the above and numerous additional therapeutic agents appropriate for the practice of the present invention are also disclosed in U.S. Patent No. 5,733,925 assigned to NeoRx Corporation, the entire disclosure of which is incorporated by reference.
[0044] Therapeutic agents may be used singly or in combination. [0045] A wide range of therapeutic agent loadings can be used in connection with the above polymeric coatings, with the amount of loading being readily determined by those of ordinary skill in the art and ultimately depending upon the condition to be treated, the nature of the therapeutic agent itself, the avenue by which the therapeutic-agent-loaded polymeric coating is administered to the intended subject, and so forth. The loaded polymeric coating will frequently comprise from 1% or less to 70 wt% or more therapeutic agent.
EXAMPLE
[0046] In this example, a cross-linking agent is applied to the surface of a stent. The therapeutic is then delivered to the stent surface within a polymer solution. When the polymer solution contacts the cross-linking agent on the surface of the stent, the polymer forms a gel, and the therapeutic is held in a crosslinked matrix on the surface of the stent. [0047] The following materials are used: (a) 2.5% (w/w) sodium alginate polymer solution (aqueous), (b) 1.0% (w/w) calcium chloride solution (aqueous), (c) Boston Scientific Express™ 8mm coronary stent, Boston Scientific, Natick MA, USA, (d) 26 gauge hypodermic needle w/ syringe, (e) stereoscopic light microscope, (f) stent spray coater, and (g) Teflon-coated mandrels.
[0048] Stents are initially spray coated with the CaCl2 solution and allowed to dry for 3 hours at 37°C. Sodium Alginate solution is then loaded into hypodermic syringe using care to eliminate any bubbles in the syringe. Dried stents are loaded onto mandrels, and using the light microscope, the needle tip is moved into a position directly over a CaCl2- coated stent strut. Gentle pressure is used to introduce the alginate solution from the needle to the stent surface. With reference to Fig. 1, and to assist in visualizing the procedure, the stent strut can be thought of as corresponding to numeral 12, the needle to numeral 14, and the alginate solution to numeral 16.
[0049] Subsequent to application of the alginate on the CaCl2-coated stent surface, the sodium alginate, which is a yellowish color, turns a noticeable shade of green. There appears to be some volume loss (shrinking) of the alginate as it gels as well. Alginate gels anywhere that CaCl2 is present, but it does not do so on bare metal. Scratching the surface with a needle after depositing the alginate reveals a gel-like substance. Prolonged exposure to the microscope lights appears to dry the alginate gel and create a crystalline surface.
[0050] Although various embodiments are specifically illustrated and described herein, it will be appreciated that modifications and variations of the present invention are covered by the above teachings and are within the purview of the appended claims without departing from the spirit and intended scope of the invention.

Claims

IN THE CLAIMS:
1. A method for providing a therapeutic-agent-containing medical device comprising: (a) providing a reactive layer comprising a cross-linking agent on a medical device surface; and (b) applying a polymer-containing layer comprising a polymer and a therapeutic agent over said reactive layer, wherein said cross-linking agent interacts with said polymer to form a cross-linked polymeric region comprising said therapeutic agent.
2. The method of claim 1 , wherein said medical device is an implantable or insertable medical device.
3. The method of claim 1, wherein said medical device is selected from a catheter, a balloon, a cerebral aneurysm filler coil and an arterio-venous shunt.
4. The method of claim 1 , wherein said medical device is a stent.
5. The method of claim 4, wherein said device is a vascular stent.
6. The method of claim 1, wherein said crosslinking agent is an ionic crosslinking agent.
7. The method of claim 6, wherein said crosslinking agent is a cationic crosslinking agent.
8. The method of claim 7, wherein said polymer is a mono-valent poly-glycosamino- glycan polymer.
9. The method of claim 8, wherein said polymer is sodium alginate.
10. The method of claim 8, wherein said crosslinking agent comprises calcium cations.
11. The method of claim 1, wherein said crosslinking agent is a covalent crosslinking agent.
12. The method of claim 11, wherein said covalent crosslinking agent covalently bonds two amino acids.
13. The method of claim 12, wherein said covalent crosslinking agent is a transglutaminase crosslinking agent.
14. The method of claim 1, wherein said polymer-containing layer further comprises water at the time of application.
15. The method of claim 1, wherein said polymer-containing layer is applied by spray coating.
16. The method of claim 1, wherein said polymer-containing layer is applied by stereo- lithographic deposition.
17. The method of claim 1, wherein said therapeutic agent comprises protein.
18. The method of claim 1, wherein said therapeutic agent comprises whole cells.
19. The method of claim 1, wherein said therapeutic agent comprises DNA.
20. The method of claim 19, wherein said therapeutic agent further comprises a vector for delivering said DNA.
21. The method of claim 20, wherein said vector is a viral vector.
22. The method of claim 18, wherein said therapeutic agent further comprises extracellular matrix components.
PCT/US2004/014283 2003-05-06 2004-05-06 Processes for producing polymer coatings WO2004098671A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04760732A EP1626751A2 (en) 2003-05-06 2004-05-06 Processes for producing polymer coatings

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/430,165 2003-05-06
US10/430,165 US6923996B2 (en) 2003-05-06 2003-05-06 Processes for producing polymer coatings for release of therapeutic agent

Publications (2)

Publication Number Publication Date
WO2004098671A2 true WO2004098671A2 (en) 2004-11-18
WO2004098671A3 WO2004098671A3 (en) 2004-12-16

Family

ID=33416196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014283 WO2004098671A2 (en) 2003-05-06 2004-05-06 Processes for producing polymer coatings

Country Status (3)

Country Link
US (2) US6923996B2 (en)
EP (1) EP1626751A2 (en)
WO (1) WO2004098671A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004579A1 (en) * 2012-06-25 2014-01-03 The Regents Of The University Of California Systems and methods for fabricating spiral coils with atomized bioactive coatings
US9044456B2 (en) 2008-06-18 2015-06-02 Lifebond Ltd. Cross-linked compositions
US9066991B2 (en) 2009-12-22 2015-06-30 Lifebond Ltd. Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US9636433B2 (en) 2006-12-15 2017-05-02 Lifebond Ltd Gelatin-transglutaminase hemostatic dressings and sealants
US9730820B2 (en) 2008-09-25 2017-08-15 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US9950341B2 (en) 2011-07-07 2018-04-24 The Regents Of The University Of California Systems and methods for fabricating spiral coils with atomized bioactive coatings

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
ATE526038T1 (en) 2003-03-28 2011-10-15 Innovational Holdings Llc IMPLANTABLE MEDICAL DEVICE WITH CONTINUOUS MEDIUM CONCENTRATION DISTANCE
US6923996B2 (en) * 2003-05-06 2005-08-02 Scimed Life Systems, Inc. Processes for producing polymer coatings for release of therapeutic agent
US8158151B2 (en) * 2004-08-10 2012-04-17 Boston Scientific Scimed, Inc. Solvent-assisted loading of therapeutic agents
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
US20060134410A1 (en) 2004-12-20 2006-06-22 Mackey Larry N Polymeric structures comprising an unsubstituted hydroxyl polymer and processes for making same
US8439964B2 (en) * 2005-08-23 2013-05-14 Boston Scientific Scimed, Inc. Stent with web-inducing nodes for increased surface area
US20070128247A1 (en) * 2005-12-01 2007-06-07 Kato Yasushi P Method for Ionically Cross-Linking Polysaccharide Material for Thin Film Applications and Products Produced Therefrom
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
DE102006035899A1 (en) * 2006-07-31 2008-02-07 Dade Behring Marburg Gmbh New polysaccharide-peptide-conjugate, where the peptide portion contains a sequence having a signal group that is splittable by thrombin at its carbon-terminal end, useful in a procedure for determining the thrombin generation in a sample
KR100745046B1 (en) * 2006-08-01 2007-08-01 주식회사 에스앤지바이오텍 Polymer injectable detachable coil
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
CA2663303A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Endoprosthesis with adjustable surface features
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
ES2368125T3 (en) 2006-09-15 2011-11-14 Boston Scientific Scimed, Inc. BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS.
EP2959925B1 (en) 2006-09-15 2018-08-29 Boston Scientific Limited Medical devices and methods of making the same
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
US20080132991A1 (en) * 2006-11-30 2008-06-05 Leonard Pinchuk Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom
EP2277563B1 (en) 2006-12-28 2014-06-25 Boston Scientific Limited Bioerodible endoprostheses and method of making the same
US8728170B1 (en) 2006-12-28 2014-05-20 Boston Scientific Scimed, Inc. Bioerodible nano-fibrous and nano-porous conductive composites
KR20120106880A (en) 2007-01-21 2012-09-26 헤모텍 아게 Medical product for treating stenosis of body passages and for preventing threatening restenosis
EP2125058B1 (en) * 2007-02-07 2014-12-03 Cook Medical Technologies LLC Medical device coatings for releasing a therapeutic agent at multiple rates
US7858337B2 (en) 2007-03-08 2010-12-28 Novartis Ag Process for the manufacture of a composite material
CA2687281A1 (en) * 2007-03-20 2008-09-25 Boston Scientific Limited Urological medical devices for release of prostatically beneficial therapeutic agents
JP5805369B2 (en) * 2007-03-20 2015-11-04 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Urological medical devices for releasing therapeutic agents
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US8309521B2 (en) 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8608049B2 (en) 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8049061B2 (en) 2008-09-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
US8076529B2 (en) 2008-09-26 2011-12-13 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix for intraluminal drug delivery
US8226603B2 (en) 2008-09-25 2012-07-24 Abbott Cardiovascular Systems Inc. Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
EP2379124B1 (en) 2008-12-01 2016-01-27 University College Cork, National University of Ireland, Cork Igf1-eluting stent for myocardial repair
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
EP2453938B1 (en) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8573018B2 (en) * 2010-01-15 2013-11-05 Essex Group, Inc. System for manufacturing wire
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
DE102010003615A1 (en) * 2010-04-01 2011-10-06 Leibniz-Institut Für Polymerforschung Dresden E.V. Process for the preparation of a drug delivery system based on polyelectrolyte complexes
DK2600910T3 (en) 2010-08-05 2016-04-04 Lifebond Ltd Wound dressings and adhesives COMPREHENSIVE DRYING FORMATIONS
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9492594B2 (en) 2014-07-18 2016-11-15 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
US11406742B2 (en) 2014-07-18 2022-08-09 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
CN104922735B (en) * 2015-06-24 2017-03-22 浙江巴泰医疗科技有限公司 Method for manufacturing medicine balloons

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153235A (en) * 1984-01-30 1985-08-21 Meadox Medicals Inc Drug delivery collagen-coated synthetic vascular graft
EP0623354A1 (en) * 1993-04-26 1994-11-09 Medtronic, Inc. Intravascular stents
WO1996032907A1 (en) * 1995-04-19 1996-10-24 Schneider (Usa) Inc. Drug release coated stent
WO2002058753A2 (en) * 2000-12-28 2002-08-01 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6517858B1 (en) * 1998-11-16 2003-02-11 Commissariat A L'energie Atomique Bioactive prostheses with immunosuppressive, antistenotic and antithrombotic properties
WO2003084583A2 (en) * 2002-04-04 2003-10-16 Scimed Life Systems, Inc. Processes for producing polymer coating through surface polymerization
WO2004000267A1 (en) * 2002-06-19 2003-12-31 Scimed Life Sytems, Inc. Method for modulation of drug release from multiphase implantable or insertable medical devices and a process for manufacturing such devices
WO2004060427A1 (en) * 2002-12-19 2004-07-22 Kimberly-Clark Worldwide, Inc. Lubricious coating for medical devices

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806355A (en) * 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
DE3866555D1 (en) * 1987-02-18 1992-01-16 Unilever Nv PLASTIFIED EDIBLE DISPERSION.
US5843089A (en) * 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5531716A (en) * 1993-09-29 1996-07-02 Hercules Incorporated Medical devices subject to triggered disintegration
US5773577A (en) * 1994-03-03 1998-06-30 Protein Polymer Technologies Products comprising substrates capable of enzymatic cross-linking
US5857998A (en) * 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5660873A (en) * 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
MX9705922A (en) * 1995-02-01 1997-10-31 Schneider Usa Inc Process for hydrophilicization of hydrophobic polymers.
US6017577A (en) * 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
US5919570A (en) * 1995-02-01 1999-07-06 Schneider Inc. Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices
US5702754A (en) * 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6368356B1 (en) 1996-07-11 2002-04-09 Scimed Life Systems, Inc. Medical devices comprising hydrogel polymers having improved mechanical properties
US6060534A (en) 1996-07-11 2000-05-09 Scimed Life Systems, Inc. Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties
US5820918A (en) * 1996-07-11 1998-10-13 Hercules Incorporated Medical devices containing in-situ generated medical compounds
US5831313A (en) * 1996-08-15 1998-11-03 Integrated Device Technology, Inc. Structure for improving latch-up immunity and interwell isolation in a semiconductor device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6270902B1 (en) * 1997-04-23 2001-08-07 C. R. Bard, Inc. Method of improving the adherence of certain crosslinked polymer coatings containing PEO or PVP to a substrate
US5879697A (en) * 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
CA2294917C (en) * 1997-06-18 2009-01-06 Boston Scientific Corporation Polycarbonate-polyurethane dispersions for thrombo-resistant coatings
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
DE19822855C1 (en) * 1998-05-22 2001-05-03 Daimler Chrysler Ag Method and device for monitoring and / or documenting a machining process carried out with a laser
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
ATE235928T1 (en) 1998-09-15 2003-04-15 Isotis Nv COATING PROCESS OF MEDICAL IMPLANTS
US6596401B1 (en) * 1998-11-10 2003-07-22 C. R. Bard Inc. Silane copolymer compositions containing active agents
US6309380B1 (en) 1999-01-27 2001-10-30 Marian L. Larson Drug delivery via conformal film
US6517888B1 (en) * 2000-11-28 2003-02-11 Scimed Life Systems, Inc. Method for manufacturing a medical device having a coated portion by laser ablation
DE10130968B4 (en) * 2001-06-27 2009-08-20 Envisiontec Gmbh Coated polymeric material, its use and process for its preparation
GB0210216D0 (en) * 2002-05-03 2002-06-12 First Water Ltd Ionically crosslinked alginate hydrogels, process for their manufacture and their use in medical devices
US6923996B2 (en) * 2003-05-06 2005-08-02 Scimed Life Systems, Inc. Processes for producing polymer coatings for release of therapeutic agent

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153235A (en) * 1984-01-30 1985-08-21 Meadox Medicals Inc Drug delivery collagen-coated synthetic vascular graft
EP0623354A1 (en) * 1993-04-26 1994-11-09 Medtronic, Inc. Intravascular stents
WO1996032907A1 (en) * 1995-04-19 1996-10-24 Schneider (Usa) Inc. Drug release coated stent
US6517858B1 (en) * 1998-11-16 2003-02-11 Commissariat A L'energie Atomique Bioactive prostheses with immunosuppressive, antistenotic and antithrombotic properties
WO2002058753A2 (en) * 2000-12-28 2002-08-01 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
WO2003084583A2 (en) * 2002-04-04 2003-10-16 Scimed Life Systems, Inc. Processes for producing polymer coating through surface polymerization
WO2004000267A1 (en) * 2002-06-19 2003-12-31 Scimed Life Sytems, Inc. Method for modulation of drug release from multiphase implantable or insertable medical devices and a process for manufacturing such devices
WO2004060427A1 (en) * 2002-12-19 2004-07-22 Kimberly-Clark Worldwide, Inc. Lubricious coating for medical devices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1626751A2 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636433B2 (en) 2006-12-15 2017-05-02 Lifebond Ltd Gelatin-transglutaminase hemostatic dressings and sealants
US9655988B2 (en) 2006-12-15 2017-05-23 Lifebond Ltd Gelatin-transglutaminase hemostatic dressings and sealants
US9044456B2 (en) 2008-06-18 2015-06-02 Lifebond Ltd. Cross-linked compositions
US9730820B2 (en) 2008-09-25 2017-08-15 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US9066991B2 (en) 2009-12-22 2015-06-30 Lifebond Ltd. Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US10202585B2 (en) 2009-12-22 2019-02-12 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US9950341B2 (en) 2011-07-07 2018-04-24 The Regents Of The University Of California Systems and methods for fabricating spiral coils with atomized bioactive coatings
WO2014004579A1 (en) * 2012-06-25 2014-01-03 The Regents Of The University Of California Systems and methods for fabricating spiral coils with atomized bioactive coatings
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions

Also Published As

Publication number Publication date
US20040224080A1 (en) 2004-11-11
EP1626751A2 (en) 2006-02-22
WO2004098671A3 (en) 2004-12-16
US6923996B2 (en) 2005-08-02
US7390525B2 (en) 2008-06-24
US20050158359A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
US7390525B2 (en) Processes for producing polymer coatings for release of therapeutic agent
US7381418B2 (en) Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
EP1786487B1 (en) Medical devices having self-forming rate-controlling barrier for drug release
US7517914B2 (en) Controlled degradation materials for therapeutic agent delivery
US7931932B2 (en) Processes for producing polymer coatings through surface polymerization
EP1660144B1 (en) Implantable or insertable medical devices containing graft copolymer for controlled delivery of therapeutic agents
US8535702B2 (en) Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
US7919110B2 (en) Medical device drug release regions containing non-covalently bound polymers
US20060013853A1 (en) Medical devices having conductive substrate and covalently bonded coating layer
US20080050415A1 (en) Polymeric/ceramic composite materials for use in medical devices
US20050220853A1 (en) Controlled delivery of therapeutic agents from medical articles
EP1513569A1 (en) Implantable or insertable medical devices for controlled delivery of a therapeutic agent
CA2666831A1 (en) Medical devices having polymeric regions based on vinyl ether block copolymers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004760732

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004760732

Country of ref document: EP